Boston Scientific (TICKER: BSX) Benchmark And Performance Data

there are 11 of samples in the benchmark for Boston Scientific in year 2022 in 2022. The total inventory for Boston Scientific was $955,000,000.00 in 2016. The total inventory for Boston Scientific was $946,000,000.00 in 2014. The total inventory for Boston Scientific was $897,000,000.00 in 2013. The total inventory for Boston Scientific was $884,000,000.00 in 2012. The total inventory for Boston Scientific was $1,610,000,000.00 in 2021. The total inventory for Boston Scientific was $1,579,000,000.00 in 2019. The total inventory for Boston Scientific was $1,351,000,000.00 in 2020. The total inventory for Boston Scientific was $1,166,000,000.00 in 2018. The total inventory for Boston Scientific was $1,078,000,000.00 in 2017. The total inventory for Boston Scientific was $1,016,000,000.00 in 2015. The sales, general, and administrative (SGA) for Boston Scientific was $4,359,000,000.00 in 2021. The sales, general, and administrative (SGA) for Boston Scientific was $3,941,000,000.00 in 2019. The sales, general, and administrative (SGA) for Boston Scientific was $3,787,000,000.00 in 2020. The sales, general, and administrative (SGA) for Boston Scientific was $3,569,000,000.00 in 2018. The sales, general, and administrative (SGA) for Boston Scientific was $3,294,000,000.00 in 2017. The sales, general, and administrative (SGA) for Boston Scientific was $3,099,000,000.00 in 2016. The sales, general, and administrative (SGA) for Boston Scientific was $2,902,000,000.00 in 2014. The sales, general, and administrative (SGA) for Boston Scientific was $2,873,000,000.00 in 2015. The sales, general, and administrative (SGA) for Boston Scientific was $2,674,000,000.00 in 2013. The sales, general, and administrative (SGA) for Boston Scientific was $2,535,000,000.00 in 2012. The sales, general, and administrative (SGA) for Boston Scientific was $$4,520,000,000 in 2022. The revenue volatility for Boston Scientific was 10.16% in 2022. The market capitalization for Boston Scientific was $79,115,619,788.00 in 2020. The market capitalization for Boston Scientific was $77,310,988,286.00 in 2021. The market capitalization for Boston Scientific was $71,920,077,420.00 in 2019. The market capitalization for Boston Scientific was $66,273,043,018.00 in 2018. The market capitalization for Boston Scientific was $63,314,288,466.00 in 2015. The market capitalization for Boston Scientific was $61,819,199,148.00 in 2013. The market capitalization for Boston Scientific was $60,792,608,657.00 in 2012. The market capitalization for Boston Scientific was $60,556,098,265.00 in 2014. The market capitalization for Boston Scientific was $55,465,534,629.00 in 2017. The market capitalization for Boston Scientific was $53,292,482,461.00 in 2016. The market capitalization for Boston Scientific was $$87,782,000,000 in 2022. The gross revenue for Boston Scientific was $9,913,000,000.00 in 2020. The gross revenue for Boston Scientific was $9,823,000,000.00 in 2018. The gross revenue for Boston Scientific was $9,048,000,000.00 in 2017. The gross revenue for Boston Scientific was $8,386,000,000.00 in 2016. The gross revenue for Boston Scientific was $7,477,000,000.00 in 2015. The gross revenue for Boston Scientific was $7,380,000,000.00 in 2014. The gross revenue for Boston Scientific was $7,249,000,000.00 in 2012. The gross revenue for Boston Scientific was $7,143,000,000.00 in 2013. The gross revenue for Boston Scientific was $11,888,000,000.00 in 2021. The gross revenue for Boston Scientific was $10,735,000,000.00 in 2019. The gross revenue for Boston Scientific was $$12,682,000,000 in 2022. The gross margin for Boston Scientific was $16.03% in 2022. The days sales outstanding for Boston Scientific was 54 days in 2022. The days payable outstanding for Boston Scientific was 75 days in 2022. The days of inventory for Boston Scientific was $159 in 2022. The cost of goods sold (COGS) for Boston Scientific was 31.56% in 2022. The cost of goods sold (COGS) for Boston Scientific was $3,760,000,000.00 in 2021. The cost of goods sold (COGS) for Boston Scientific was $3,510,000,000.00 in 2020. The cost of goods sold (COGS) for Boston Scientific was $3,181,000,000.00 in 2019. The cost of goods sold (COGS) for Boston Scientific was $2,883,000,000.00 in 2018. The cost of goods sold (COGS) for Boston Scientific was $2,661,000,000.00 in 2017. The cost of goods sold (COGS) for Boston Scientific was $2,503,000,000.00 in 2016. The cost of goods sold (COGS) for Boston Scientific was $2,502,000,000.00 in 2012. The cost of goods sold (COGS) for Boston Scientific was $2,321,000,000.00 in 2014. The cost of goods sold (COGS) for Boston Scientific was $2,314,000,000.00 in 2013. The cost of goods sold (COGS) for Boston Scientific was $2,243,000,000.00 in 2015. The cost of goods sold (COGS) for Boston Scientific was $$4,003,000,000 in 2022. The cash to cash cycle time for Boston Scientific was 138 in 2022. The annual percentage growth rate of Boston Scientific was -0.07% in 2022. Boston Scientific in its benchmark peer group, had rank 7 for sales growth in 2022. Boston Scientific in its benchmark peer group, had rank 6 for cash to cash cycle time in 2022. Boston Scientific in its benchmark peer group, had rank 6 days for days of inventory in 2022. Boston Scientific in its benchmark peer group, had rank 5 days for days sales outstanding in 2022. Boston Scientific in its benchmark peer group, had rank 4 for cost of goods sold as a percent of revenue in 2022. Boston Scientific in its benchmark peer group, had rank 3 for gross revenue in 2022. Boston Scientific headquarters region is East. Boston Scientific has ticker symbol BSX. Boston Scientific has the following profile: Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.. Boston Scientific has primary indstury Medical Devices. Boston Scientific had a $$5,767,000,000 gap between actual performance and next performance rank for gross revenue in competitive benchmarking in 2022. Boston Scientific had Abbott Laboratories, and QuidelOrtho, and Zimmer Biomet, and Edwards Lifesciences, and Bio-Rad Laboratories, and Boston Scientific, and Align Technology, and Stryker, and AdaptHealth, and Bruker, and DexCom benchmark peer companies for its SIC code in 2022. Boston Scientific had 51 days gap between actual performance and next performance rank for days of inventory in competitive benchmarking in 2022. Boston Scientific had 45,000 number of employees in 2022. Boston Scientific had 2.46% gap between actual performance and next performance rank for cost of goods sold as a percent of revenue in competitive benchmarking in 2022. Boston Scientific had 19 days gap between actual performance and next performance rank for cash to cash in competitive benchmarking in 2022. Boston Scientific had 10 days gap between actual performance and next performance rank for days sales outstanding in competitive benchmarking in 2022. Boston Scientific had 1.15% gap between actual performance and next performance rank for gross margin in competitive benchmarking in 2022. Boston Scientific had 0.27% gap between actual performance and next performance rank for sales volatility in competitive benchmarking in 2022. Boston Scientific had 0.02% gap between actual performance and next performance rank for sales growth in competitive benchmarking in 2022. Boston Scientific can reduce overall cost by $$1,086,000,000 by improving both COGS and SGA to next benchmark tier in 2022. Boston Scientific can reduce inventory with practices including SKU Reduction in 2022. Boston Scientific can reduce inventory with practices including Reduce Manufacturing Latency in 2022. Boston Scientific can reduce inventory with practices including Forecast Accuracy in 2022. Boston Scientific can reduce inventory with practices including Demand Shaping in 2022. Boston Scientific can reduce days sales outstanding with practices including in 2022. Boston Scientific can increase sales revenue by $$5,767,000,000 improving sales performance to next benchmark tier in 2022. Boston Scientific can increase revenue growth by $$3,000,000 by improving growth performance to next benchmark tier in 2022. Boston Scientific can increase overall revenue by $$5,770,000,000 by improving both growth and sales performance to next benchmark tier in 2022. Boston Scientific can increase days payables outstanding with practices including Strategic Sourcing in 2022. Boston Scientific can increase days payables outstanding by $382,000,000 days by increasing days payables outstanding to next benchmark tier in 2022. Boston Scientific can improve total financial performance by $$9,357,000,000 by improving revenue, costs, and working capital in 2022. Boston Scientific can decrease overall working capital by $$2,502,000,000 by improving inventory, payables and receivables to next benchmark tier in 2022. Boston Scientific can decrease inventory days by $1,772,000,000 days by reducing inventory days to next benchmark tier in 2022. Boston Scientific can decrease days sales outstanding by $347,000,000 days by reducing days sales outstanding to next benchmark tier in 2022. Boston Scientific can accelerate revenue growth practices including Revenue-optimized Planning in 2022. Boston Scientific can accelerate revenue growth practices including Pricing Optimization in 2022. Boston Scientific can accelerate revenue growth practices including Accelerate Design Pipeline in 2022. 94 days was the measured superior or top ten performance level for days of inventory in Boston Scientific's peer group in 2022. 9.89% was the measured superior or top ten performance level for sales volatility in Boston Scientific's peer group in 2022. 75 days was the measured superior or top ten performance level for cash to cash cycle time in Boston Scientific's peer group in 2022. 60 days was the measured parity or middle performance level for days sales outstanding in Boston Scientific's peer group in 2022. 53 days was the measured advantage or top third performance level for days sales outstanding in Boston Scientific's peer group in 2022. 44 days was the measured superior or top ten performance level for days sales outstanding in Boston Scientific's peer group in 2022. 37.24% was the measured parity or middle performance level for cost of goods sold as a percent of revenue in Boston Scientific's peer group in 2022. 31.56% was the measured advantage or top third performance level for cost of goods sold as a percent of revenue in Boston Scientific's peer group in 2022. 30.00% was the measured superior or top ten performance level for gross margin in Boston Scientific's peer group in 2022. 29.10% was the measured superior or top ten performance level for cost of goods sold as a percent of revenue in Boston Scientific's peer group in 2022. 159 days was the measured parity or middle performance level for days of inventory in Boston Scientific's peer group in 2022. 138 days was the measured parity or middle performance level for cash to cash cycle time in Boston Scientific's peer group in 2022. 13.32% was the measured parity or middle performance level for sales volatility in Boston Scientific's peer group in 2022. 119 days was the measured advantage or top third performance level for cash to cash cycle time in Boston Scientific's peer group in 2022. 11.40% was the measured advantage or top third performance level for sales volatility in Boston Scientific's peer group in 2022. 108 days was the measured advantage or top third performance level for days of inventory in Boston Scientific's peer group in 2022. 0.04% was the measured superior or top ten performance level for sales growth in Boston Scientific's peer group in 2022. -0.05% was the measured parity or middle performance level for sales growth in Boston Scientific's peer group in 2022. -0.02% was the measured advantage or top third performance level for sales growth in Boston Scientific's peer group in 2022. $18.02% was the measured advantage or top third performance level for gross margin in Boston Scientific's peer group in 2022. $17.18% was the measured parity or middle performance level for gross margin in Boston Scientific's peer group in 2022. $$6,940,000,000 was the measured advantage or top third performance level for gross revenue in Boston Scientific's peer group. $$3,735,000,000 was the measured parity or middle performance level for gross revenue in Boston Scientific's peer group in 2022. $$18,449,000,000 was the measured superior or top ten performance level for gross revenue in Boston Scientific's peer group in 2022.